Phosphorothioate oligodeoxynucleotides distribute similarly in class a scavenger receptor knockout and wild-type mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 2, 2000, Pages 489-496

  Butler, Madeline ^a   Crooke, Rosanne M ^a   Graham, Mark J ^a   Lemonidis, Kristina M ^a   Lougheed, Marilee ^a,b   Murray, Susan F ^a   Witchell, Donna ^a   Steinbrecher, Urs ^a   Bennett, C Frank ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGODEOXYNUCLEOTIDE; PHOSPHOROTHIOIC ACID; SCAVENGER RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; GEL ELECTROPHORESIS; GENE TARGETING; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; KUPFFER CELL; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY;

ANIMALS; CELLS, CULTURED; ELECTROPHORESIS, CAPILLARY; IMMUNOHISTOCHEMISTRY; KIDNEY; KUPFFER CELLS; LIVER; LUNG; MACROPHAGES, PERITONEAL; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LIPOPROTEIN; RECEPTORS, SCAVENGER; RNA; SCAVENGER RECEPTORS, CLASS A; SCAVENGER RECEPTORS, CLASS B; SPLEEN; THIONUCLEOTIDES;

EID: 0033984862     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Agrawal S, Temsamani J, Galbraith W and Tang J (1995) Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28:7-16.
2. Agrawal S, Temsamani J and Tang JY (1991)Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88:7595-7599.
3. Benimetskaya L, Tonkinson JL, Koziolkiewicz M, Karowski B, Guga P, Zeltser R, Stec W and Stein CA (1995) Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin, and fibronectin is P-chirality independent. Nucleic Acids Res 23:4239-4245.
4. Bennett CF, Chiang M-Y, Chan H, Shoemaker JEE and Mirabelli CK (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41:1023-1033.
5. Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W and Jacoby HI (1997) An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther 280:988-1000.
6. Berry MN and Friend DS (1972) High yield preparation of isolated rat liver parenchymal cells: A biochemical and fine structure analysis. J Cell Biol 59:722-734.
7. Bijsterbosch MK, Manoharan M, Rump E, De Vrueh RLA, van Veghel R, Tivel K, Biessen EA, Bennett CF, Cook PD and van Berkel TJC (1997) In vivo fate of phosphorothioate oligodeoxynucleotides: Predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 25:3290-3296.
8. Brown MS, Basu SK, Falck JR, Ho YK and Goldstein JL (1980) The scavenger cell pathway for lipoprotein degradation: Specificity of the binding site that mediates the uptake of negatively charged LDL by macrophages. J Supramol Struct 13:67-81.
9. Butler M, Stecker K and Bennett CF (1997) Histological localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue. Lab Invest 77:379-388.
10. Cioffi CL, Garay M, Johnston JL, McGraw K, Boggs RT, Hreniuk D and Monia BP (1997) Selective inhibition of A-Raf and C-Raf expression by antisense oligonucleotides in rat vascular smooth muscle cells: Role of A-Raf and C-Raf in serum-induced proliferation. Mol Pharmacol 51:383-389.
11. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther 269:89-94.
12. Crooke ST (1998) Antisense therapeutics, in Biotechnology and Safety Assessment (Thomas JA ed) pp 23-60, Taylor & Francis, Philadelphia, PA.
13. Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Guinosso CJ, Kornbrust D, Manoharan M, Sasmor HM, Schleich T, Tivel KL and Griffey RH (1996) Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 277:923-937.
14. Dean NM and McKay R (1994) Inhibition of protein kinase C expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 91:11762-11766.
15. Dean NM, McKay R, Condon TP and Bennett CF (1994) Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 269:16416-16424.
16. Deschenes J, Valet JP and Marceau N (1982) Hepatocytes from newborn and weanling rats in monolayer culture: Isolation by perfusion, fibronectin-mediated adhesion, spreading and functional activities. In Vitro 16:722-730.
17. Fraser I, Hughes D and Gordon S (1993) Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor. Nature (Lond) 364:343-346.
18. Geary RS, Leeds JM, Fitchett J, Burckin T, Troung L, Spainhour C, Creek M and Levin AA (1997) Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos 25:1272-1281.
19. Goldstein JL, Ho YK, Basu SK and Brown MS (1979) Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 76:333-337.
20. Graham MJ, Crooke ST, Monteith DK, Copper SR, Lemonidis KM, Stecker KK, Martin MJ and Crooke RM (1998) In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 286:447-458.
21. Graham MJ, Freier SM, Crooke RM, Ecker DJ, Maslova RN and Lesnik EA (1993) Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res 21:3737-3743.
22. Haberland M and Fogelman A (1985) Scavenger receptor-mediated recognition of maleyl bovine plasma albumin and the demaleylated protein in human monocyte-macrophages. Proc Natl Acad Sci USA 82:2693-2697.
23. Hughes DA, Fraser IP and Gordon S (1995) Murine macrophage scavenger receptor: In vivo expression and function as receptor for macrophage adhesion in lymphoid and non-lymphoid tissues. Eur J Immunol 25:466-473.
24. 3H-1,2-benzodithiole-3-one 1.1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates. J Am Chem Soc 112:1253-1254.
25. Krieger M and Herz J (1994) Structures and functions of multiligand lipoprotein receptors: Macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 63:601-637.
26. Lougheed M, Lum CM, Ling W, Suzuki H, Kodama T and Steinbrecher U (1997) High affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger class A type I/II. J Biol Chem 272:12938-12944.
27. Lougheed M, Zhang H and Steinbrecher U(1991) Oxidized low density lipoprotein is resistant to cathepsins and accumulates within macrophages. J Biol Chem 266: 14519-14525.
28. Monia BP and Dean NM (1998) Pharmacological activity of antisense oligonucleotides in animal models of disease, in Antisense Research and Applications (Crooke S ed) pp 427-443, Springer-Verlag, Berlin.
29. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF and Freier SM (1992) Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 267:19954-19962.
30. Naito M, Kodama T, Matsumoto A, Doi T and Takahashi K (1991) Tissue distribution, intracellular localization, and in vitro expression of bovine macrophage scavenger receptors. Am J Pathol 139:1411-1423.
31. Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM and Klotman PE (1995) Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy. Kidney Int 47:1462-1469.
32. Sawai K, Mahato RI, Oka Y, Takakura Y and Hashida M (1996) Disposition of oligonucleotides in isolated perfused rat kidney: Involvement of scavenger receptors in their renal uptake. J Pharmacol Exp Ther 279:284-290.
33. Steinbrecher U (1999) Receptors for oxidized low density lipoprotein. Biochim Biophys Acta 1436:279-298.
34. Steward A, Christian RA, Hamilton KO and Nicklin PL (1998) Co-administration of polyanions with a phosphorothioate oligodeoxynucleotide (CGP 69846A): A role for the scavenger receptor in its in vivo disposition. Biochem Pharmacol 56:509-516.
35. Storm ST, Cleveland JL and Rapp U (1990) Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene 5:345-351.
36. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Horiuchi S, Takahashi K, Kruijt JK, van Berkel TJC, Steinbrecher UP, Ishibashi S, Maeda N, Gordon S and Kodama T (1997) A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature (Lond) 386:292-296.
37. Takakura Y, Takagi T, Hashiguchi M, Nishikawa M, Yamashita F, Doi T, Imanishi T, Suzuki H, Kodama T and Hashida M (1999) Characterization of plasmid DNA binding and uptake by peritoneal macrophages from class A scavenger receptor knockout mice. Pharm Res 16:503-508.
38. Terpstra, V, Kondratenko N and Steinberg D (1997) Macrophages lacking scavenger receptor A show a decrease in binding and uptake of acetylated low-density lipoprotein and of apoptotic thymocytes, but not of oxidatively damaged red blood cells. Proc Natl Acad Sci USA 94:8127-8131.